Skip to main content
. Author manuscript; available in PMC: 2023 Feb 2.
Published in final edited form as: Clin Cancer Res. 2022 Aug 2;28(15):3242–3247. doi: 10.1158/1078-0432.CCR-21-3867

Table 2.

Any ≥ Grade 3 AEs That Occurred in ≥ 1 Patient and Non-Hematologic AEs of Interest

Event of Interest ≥ Grade 3 Any Grade
Hematologic AEs, no. (%)
Thrombocytopenia 8 (24) 20 (59)
Anemia 6 (18) 19 (56)
Neutropenia 4 (12) 13 (38)
Lymphocyte count increased 2 (6) 10 (29)
Lymphopenia 4 (12) 9 (27)
Non-hematologic AEs, no. (%)
Fatigue 0 (0) 19 (56)
Nausea 1 (3) 18 (53)
Anorexia 0 (0) 14 (41)
Diarrhea 2 (6) 14 (41)
Hypertension 6 (18) 12 (35)
Joint/Bone Pain 1 (3) 12 (35)
Hyponatremia 5 (15) 10 (29)
Pneumonia 3 (9) 9 (27)
Hyperglycemia 2 (6) 9 (27)
Weight Loss 0 (0) 9 (27)
Fall 2 (6) 5 (15)
Bleeding* 0 (0) 4 (12)
Cataract 2 (6) 4 (12)
Cognitive Disturbance 2 (6) 4 (12)
Hypophosphatemia 2 (6) 4 (12)
Arthralgia 0 (0) 3 (9)
Atrial Fibrillation 0 (0) 3 (9)
Death 3 (9) 3 (9)
Hypoxia 2 (6) 2 (6)
*

Grade 1/2 epistaxis (n=2), hematuria (n=1), menorrhagia (n=1)